Acute respiratory distress syndrome phenotypes and identifying treatable traits the dawn of personalized medicine for ARDS

American Journal of Respiratory and Critical Care Medicine

Volumn 195, Issue 3, 2017, Pages 280-281

  Shankar Hari, Manu ^a,b   McAuley, Daniel F ^c,d  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT RESPIRATORY DISTRESS SYNDROME; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; EDITORIAL; HUMAN; HYPOTENSION; INFLAMMATION; MORTALITY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; TREATMENT RESPONSE; ARTIFICIAL VENTILATION; GENETICS; PHENOTYPE;

HUMANS; PHENOTYPE; PRECISION MEDICINE; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 85014775379     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201608-1729ED     Document Type: Editorial

References (14)

1. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-2533.
2. Sweeney Mac R, McAuley DF. Acute respiratory distress syndrome. Lancet 2016;388:2416-2430.
3. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, et al.; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016;315:788-800.
4. Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, Scales DC, Stather DR, Li A, Jones A, et al. Has mortality from acute respiratory distress syndrome decreased over time? a systematic review. Am J Respir Crit Care Med 2009;179:220-227.
5. Rubenfeld GD, Caldwell E, Granton J, Hudson LD, Matthay MA. Interobserver variability in applying a radiographic definition for ARDS. Chest 1999;116:1347-1353.
6. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000;21:121-145.
7. Rubenfeld GD. Confronting the frustrations of negative clinical trials in acute respiratory distress syndrome. Ann Am Thorac Soc 2015;12:S58-S63.
8. Lazarsfeld PF, Henry NW. Latent structure analysis. Boston, MA: Houghton Mifflin; 1968.
9. Dean N, Raftery AE. Latent class analysis variable selection. Ann Inst Stat Math 2010;62:11-35.
10. van Smeden M, Naaktgeboren CA, Reitsma JB, Moons KG, de Groot JA. Latent class models in diagnostic studies when there is no reference standard: a systematic review. Am J Epidemiol 2014;179:423-431.
11. Rindskopf D, Rindskopf W. The value of latent class analysis in medical diagnosis. Stat Med 1986;5:21-27.
12. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, Network NA; NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014;2:611-620.
13. Famous KR, Delucchi K,Ware LB, Kangelaris KN, Liu KD, Thompson BT, Calfee CS; ARDS Network. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 2017;195:331-338.
14. Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med 2016;194:147-155.